Editorial: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae?

Nurgali, Kulmira; Jagoe, R. Thomas; Abalo, Raquel

doi:10.3389/fphar.2018.00245

Cited by 763 publications

(491 citation statements)

References 5 publications

Supporting

Mentioning

477

Contrasting

Unclassified

Order By: Relevance

“…Cancer chemotherapy is associated with the development of numerous and feared adverse effects that may compromise treatment. 1 Adverse effects in the gastrointestinal tract include nausea and emesis, and diarrhea or constipation, depending on the particular drug. [1][2][3][4][5] Cisplatin is a highly emetogenic antitumoral drug, often used as reference in experimental studies searching for new antiemetics.…”

Section: Introductionmentioning

confidence: 99%

“…1 Adverse effects in the gastrointestinal tract include nausea and emesis, and diarrhea or constipation, depending on the particular drug. [1][2][3][4][5] Cisplatin is a highly emetogenic antitumoral drug, often used as reference in experimental studies searching for new antiemetics. 6,7 Although other mechanisms may be involved, serotonin released from the enterochromaffin cells and acting upon vagal afferents through 5-HT 3 receptors is one of the main components underlying nausea and emesis induced by cisplatin [8][9][10][11] and is probably also involved in the effect of other antitumoral drugs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Alterations of colonic sensitivity and gastric dysmotility after acute cisplatin and granisetron

Martín‐Ruíz

Uranga

Mosińska

et al. 2018

Neurogastroenterology Motil

Self Cite

View full text Add to dashboard Cite

Background Cisplatin is a highly emetogenic antineoplastic drug and induces peripheral neuropathy when given in cycles. Granisetron, a 5‐HT3 antagonist, is clinically used to prevent chemotherapy‐induced nausea/emesis and abdominal pain in irritable bowel syndrome. The effects of cisplatin on visceral sensitivity and those of granisetron in the context of cancer chemotherapy are not well known. Methods Adult male Wistar rats received two intraperitoneal injections 30 minutes apart: granisetron (1 mg kg−1)/vehicle and cisplatin (6 mg kg−1)/vehicle. Thereafter, nausea‐like behavior was measured as bedding intake for 4 hours, and gastric dysmotility was measured radiographically for 8 hours. Gastric weight and size were determined ex vivo and samples of the forestomach, corpus, ileum, and colon were obtained for histological analysis at 4 and 30 hours after cisplatin/vehicle. Visceral sensitivity was measured as abdominal contractions in response to mechanical intracolonic stimulation 2 hours after cisplatin/vehicle. Key Results Cisplatin‐induced bedding intake and gastric dysmotility, and granisetron blocked these effects, which occurred in the absence of frank mucositis. Visceral sensitivity was reduced to a similar extent by both drugs alone or in combination. Conclusions and Inferences Cisplatin‐induced bedding intake and gastric dysmotility were blocked by granisetron, confirming the involvement of serotonin acting on 5‐HT3 receptors. Unexpectedly, visceral sensitivity to colonic distension was reduced, to the same extent, by cisplatin, granisetron, and their combination, suggesting important mechanistic differences with nausea and gastric dysmotility that warrant further investigation.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Alterations of colonic sensitivity and gastric dysmotility after acute cisplatin and granisetron

Martín‐Ruíz

Uranga

Mosińska

et al. 2018

Neurogastroenterology Motil

Self Cite

View full text Add to dashboard Cite

show abstract

“…[ 1 ] Many modern cancer therapies have the potential to be effective in killing the tumor but so often lack the high specificity and selectivity required to prevent the onset of severe side effects. [ 2,3 ] Nanotechnology holds much promise in solving these major targeting issues. Specifically referring to cell membrane‐based nanomedicines, it appears that through the marriage of the physical properties of nanomaterials with the natural biointerfacing capabilities of the cell membrane, new therapeutics can be engineered to possess multimodal functionalities including the ability to differentiate cancer cells from healthy cells, effectively delivering a payload or alternative killing modality to the target site, and reducing nonspecific toxicity coupled with the ability to evade the immune system.…”

Section: Introductionmentioning

confidence: 99%

Cell Membrane Nanotherapeutics: From Synthesis to Applications Emerging Tools for Personalized Cancer Therapy

Sevencan

McCoy

Ravisankar

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

Over the last decade, researchers have focused on developing an ideal cancer nanomedicine with robust biointerfacing, precise tumor targeting, and effective tumor killing ability. While synthetic approaches have been widely investigated, cell membrane nanotechnology has been attracting growing interest in the nanomedicine field since it enables researchers to exploit the various functions of cells. Prior to development of cell membrane nanotechnology, synthetic cell membrane‐like structures had been employed in nanomedicine. In this review, first a brief comparison between cell membrane and cell membrane‐like structures is provided and the generalized structure and functions of cell membrane are summarized. Cell membrane extraction methods and cell membrane‐based nanoparticle synthesis methods are explained. In addition, applications of these nanotechnologies in many biomedical applications are reviewed. Finally, a perspective of the future prospects and limitations of cell membrane nanotechnology is given. As with many new technologies, there are issues, which when overcome, can allow the potential of cell membrane nanotechnology for future personalized cancer nanomedicine.

show abstract

“…Cancer is a serious disease and one of the most important causes of death in the world . One of the problems in the treatment of this disease is the unwanted effects of drugs on the normal cells of the body . Cancer cells differ from the normal ones in some metabolic pathways.…”

Section: Introductionmentioning

confidence: 99%

“…1 One of the problems in the treatment of this disease is the unwanted effects of drugs on the normal cells of the body. 2 Cancer cells differ from the normal ones in some metabolic pathways. The inability to synthesis certain amino acids and the need to obtain them from the surrounding environment is one of these differences.…”

Section: Introductionmentioning

confidence: 99%

In silico identification and characterization of antineoplastic asparaginase enzyme from endophytic bacteria

et al. 2020

View full text Add to dashboard Cite

It is generally accepted that L‐asparagine is an important amino acid required for the fast growth of cells. Cancerous cells receive this amino acid from extracellular sources. The depletion of L‐asparagine from its surrounding environments by asparaginase enzyme can be used as a therapeutic strategy in cancer patients. This therapeutic enzyme is produced commercially mainly from bacteria such as Escherichia coli and Erwinia chrysanthemi. The side effects of such drugs have persuaded scientists to find new enzyme sources. In this study, in silico approach was applied to investigate L‐asparaginase producing endophytic bacteria that produce more compatible enzymes within the body. Protein–protein basic local alignment search tool with E. coli and E. chrysanthemi asparaginase enzyme sequences against 262 endophytic bacteria were performed. The results with identity more than 35%, coverage more than 80%, and E‐value less than 10−4 were selected. Then, some of bioinformatics tools were used to characterize them. A total of nine sequences consisting of seven known and two hypothetical proteins were identified in six bacterial species. The results showed that some of the asparaginase enzymes produced by endophytic bacteria possess more suitable immunological indices compared with asparaginase enzymes of E. coli and E. chrysanthemi. Herbaspirillum rubrisubalbicans was predicted to produce a nonallergen and nonantigen asparaginase enzyme. The number of antigenic determinants was predicted to be lower in asparaginase enzymes produced by Bacillus amyloliquefaciens, H. rubrisubalbicans, and H. seropedicae. Moreover, the number of high‐scored B‐cell epitopes was lower in enzyme sequences related to the mentioned bacteria and Paenibacillus polymyxa. The number of discontinuous epitopes and the number of T‐cell epitopes were lower in B. amyloliquefaciens produced enzymes. Therefore, the therapeutic use of these enzymes is possible.

show abstract

Editorial: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae?

Cited by 763 publications

References 5 publications

Alterations of colonic sensitivity and gastric dysmotility after acute cisplatin and granisetron

Alterations of colonic sensitivity and gastric dysmotility after acute cisplatin and granisetron

Cell Membrane Nanotherapeutics: From Synthesis to Applications Emerging Tools for Personalized Cancer Therapy

In silico identification and characterization of antineoplastic asparaginase enzyme from endophytic bacteria

Contact Info

Product

Resources

About